2022
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding
Li D, Ong S, Hughes M, Hung K, Agarwal R, Alexis J, Damianos J, Sharma S, Pires J, Nanna M, Laine L. Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 2022, 57: 94-102. PMID: 36394111, DOI: 10.1111/apt.17278.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsGastrointestinal bleedingPrimary preventionCardiovascular eventsRisk of MACEYale-New Haven HospitalPrimary cardiovascular preventionAdverse cardiovascular eventsKaplan-Meier curvesLong-term outcomesRisk-benefit ratioLog-rank testAspirin 81Hospitalised patientsPrimary endpointSecondary endpointsCardiovascular preventionSubsequent hospitalisationMedian ageDeprescriptionHigh riskAspirinHospitalisationPatientsPrevention
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2019
Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease
Faye AS, Hung KW, Cheng K, Blackett JW, Mckenney AS, Pont AR, Li J, Lawlor G, Lebwohl B, Freedberg DE. Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019, 26: 1394-1400. PMID: 31689354, PMCID: PMC7534414, DOI: 10.1093/ibd/izz269.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseVTE prophylaxisProphylaxis ratesVenous thromboembolismBowel diseaseVTE prophylaxis ratesVTE prophylaxis useBlood transfusion rateRetrospective cohort studyVenous thromboembolism prophylaxisStrong independent predictorExposure of interestChronic bleedingProphylaxis useThromboembolism prophylaxisTransfusion rateCohort studyHospitalized patientsIndependent predictorsPrimary outcomeHemoglobin levelsMedical recordsHematocheziaProphylaxisPatientsHematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients With Inflammatory Bowel Disease
Faye A, Hung K, Blackett J, Pont A, Lawlor G, Lichtiger S, Lebwohl B, Freedberg D. Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients With Inflammatory Bowel Disease. Gastroenterology 2019, 157: e24-e25. DOI: 10.1053/j.gastro.2019.05.019.Peer-Reviewed Original Research